C12N 2730/10141
Use of virus, viral particle or viral elements as a vector
C12N2730/10141 (Use of virus, viral particle or viral elements as a vector) appears on 36 US grants and 79 published applications in this corpus.
Search patents in C12N- Granted patents
- 36
- Published applications
- 79
- Assignees
- 47
- Inventors
- 149
- Latest grant
- 28 Apr 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 1 |
| 2002 | 0 | 0 |
| 2003 | 2 | 5 |
| 2004 | 0 | 1 |
| 2005 | 0 | 3 |
| 2006 | 3 | 4 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 2 |
| 2010 | 1 | 1 |
| 2011 | 0 | 3 |
| 2012 | 0 | 8 |
| 2013 | 1 | 2 |
| 2014 | 3 | 5 |
| 2015 | 0 | 4 |
| 2016 | 2 | 6 |
| 2017 | 2 | 4 |
| 2018 | 3 | 4 |
| 2019 | 2 | 2 |
| 2020 | 3 | 6 |
| 2021 | 2 | 1 |
| 2022 | 3 | 8 |
| 2023 | 1 | 1 |
| 2024 | 1 | 2 |
| 2025 | 4 | 0 |
| 2026 | 2 | 4 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2730/10143Viral genome or elements thereof as genetic vectorIndexing code23
- C12N 2730/10142Virus or viral particle as vehicleIndexing code9
- C12N 2730/10144Chimeric viral vector comprising heterologous viral elements for production of another viralIndexing code3
- C12N 2730/10145Special targeting system for viral vectorsIndexing code1
Recent patents
- Hepadnavirus capsid protein heterodimers and virus-like particles28 Apr 2026US 12,612,433 B2The Trustees of Indiana University
- Composition for regulating production of interfering ribonucleic acid24 Mar 2026US 12,584,129 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid23 Dec 2025US 12,503,697 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid2 Dec 2025US 12,486,506 B1Wyvern Pharmaceuticals Inc.
- Composition for regulating production of interfering ribonucleic acid25 Nov 2025US 12,480,121 B1Wyvern Pharmaceuticals Inc.
- Viral open reading frames, uses thereof, and methods of detecting the same30 Jul 2026US 2026/0218238 A1President and Fellows of Harvard College
- Compositions and methods for treating genetic disorders9 Jul 2026US 2026/0191908 A1
- Composition for regulating production of interfering ribonucleic acid26 Mar 2026US 2026/0085312 A1Wyvern Pharmaceuticals Inc.
- HBV Surface Antigen Specific T Cell Receptors And Uses Thereof22 Jan 2026US 2026/0021140 A1Scg Cell Therapy Pte. Ltd
- VLP Stabilized Vaccine Compositions9 May 2024US 2024/0148852 A1Inventprise, LLC
Most cited
By later US patents
- Recombinant hepatitis virus vectors115US 5,981,274 A1999
- Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof45US 7,842,489 B2Cellectis · 2010
- Modification of virus tropism and host range by viral genome shuffling34US 6,596,539 B1Maxygen, Inc. · 2003
- Antigen arrays for treatment of allergic eosinophilic diseases18US 7,094,409 B2Cytos Biotechnology AG · 2006
- Hepatitis B virus vectors for gene therapy7US 7,001,760 B22006